Skip to main content
DAEWOONG PHARMA logo

DAEWOONG PHARMA — Investor Relations & Filings

Ticker · 069620 ISIN · KR7069620003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2024-02-27 AGM Information
Country KR South Korea
Listing KO 069620

About DAEWOONG PHARMA

http://crm.daewoong.co.kr/eng/main

Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daewoong Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and remuneration limits. While it contains financial data, this is provided as part of the proxy materials to inform shareholders for the upcoming vote, rather than being the Annual Report itself. Therefore, it is classified as Proxy Solicitation & Information Statement.
2024-02-27 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) for Daewoong Pharmaceutical. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, proxy solicitation details, and financial statements (balance sheet, income statement, etc.) as required by Korean law for proxy solicitation materials. This document is a formal proxy statement sent to shareholders to request their votes for the AGM.
2024-02-27 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Daewoong Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the date of the upcoming general meeting of shareholders to approve the dividend. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-26 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Daewoong Pharmaceutical. It outlines the date, location, and agenda items, including the election of directors and auditors, and the approval of remuneration limits. This type of document is a standard proxy solicitation and information statement provided to shareholders prior to an annual general meeting.
2024-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding a change in sales or profit structure (30% or more). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year compared to the previous year. This type of disclosure is a standard regulatory requirement in the Korean market (KRX) for reporting significant financial changes before the final audit report is published. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and the reasons for the performance changes. FY 2023
2024-02-05 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Disclosure' (영업(잠정)실적) from Daewoong Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the 4th quarter of 2023. Since it is an initial announcement of quarterly financial results containing key highlights rather than a full comprehensive report, it falls under the 'Earnings Release' category. Q4 2023
2024-02-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.